Journal Watch · Frontiers in Immunology · 2026

Reticular dysgenesis caused by AK2 deficiency: clinical spectrum and hematopoietic stem cell transplantation outcomes in 10 patients from a single-center.

Seven patients underwent HSCT at a median age of 4 months using matched sibling, haploidentical, or cord blood donors; six survived, yielding a post-transplant survival of 85.7% with a median follow-up of 10 years, and achieved full donor myeloid and lymphoid engraftment with robust immune reconstitution.<h4>Discussion</h4>These findings demonstrate that <i>AK2</i>-related RD presents with a distinctive neonatal phenotype and carries high pre-transplant mortality, while early HSCT enables durable engraftment and favorable long-term outcomes, supporting the importance of early diagnosis and newborn screening in high-consanguinity populations.

Alaqeel B, Aljohani F, Alrumayan N et al.Frontiers in Immunology3 min readPharma relevance 55/100

DOI: 10.3389/fimmu.2026.1829403PMID: 42112325Study type: cohort / observational clinical study

TL;DR

Seven patients underwent HSCT at a median age of 4 months using matched sibling, haploidentical, or cord blood donors; six survived, yielding a post-transplant survival of 85.7% with a median follow-up of 10 years, and achieved full donor myeloid and lymphoid engraftment with robust immune reconstitution.<h4>Discussion</h4>These findings demonstrate that <i>AK2</i>-related RD presents with a distinctive neonatal phenotype and carries high pre-transplant mortality, while early HSCT enables durable engraftment and favorable long-term outcomes, supporting the importance of early diagnosis and newborn screening in high-consanguinity populations.

Key findings

  • Arg175Pro) was identified in nine patients, while one patient harbored a start-loss variant.
  • Seven patients underwent HSCT at a median age of 4 months using matched sibling, haploidentical, or cord blood donors; six survived, yielding a post-transplant survival of 85.7% with a median follow-up of 10 years, and achieved full donor myeloid and lymphoid engraftment with robust immune reconstitution.<h4>Discussion</h4>These findings demonstrate that <i>AK2</i>-related RD presents with a distinctive neonatal phenotype and carries high pre-transplant mortality, while early HSCT enables durable engraftment and favorable long-term outcomes, supporting the importance of early diagnosis and newborn screening in high-consanguinity populations.

Numbers at a glance (from the abstract)

85.7%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A recurrent homozygous missense variant (<i>AK2</i>: NM_001625.4: c.524G>C; p.

Full abstract (original)

Background: <h4>Introduction</h4>Reticular dysgenesis (RD), caused by biallelic variants in <i>AK2</i>, represents the most severe and rare form of Severe Combined Immunodeficiency, characterized by profound defects in lymphoid and myeloid lineages; however, data on its clinical spectrum and hematopoietic stem cell transplantation (HSCT) outcomes remain scarce.<h4>Methods</h4>In this retrospective single-center study, we analyzed genetically confirmed <i>AK2</i>-related RD cases managed at King Faisal Specialist Hospital and Research Centre between 2005 and 2025, reviewing clinical, immunologic, genetic, and transplant-related data.<h4>Results</h4>Ten patients from eight unrelated families were included, most with parental consanguinity, all presenting in the neonatal period with severe infections, neutropenia unresponsive to granulocyte colony-stimulating factor, and bilateral sensorineural hearing loss.

What they did: A recurrent homozygous missense variant (<i>AK2</i>: NM_001625.4: c.524G>C; p.

Results & conclusions: Arg175Pro) was identified in nine patients, while one patient harbored a start-loss variant. Seven patients underwent HSCT at a median age of 4 months using matched sibling, haploidentical, or cord blood donors; six survived, yielding a post-transplant survival of 85.7% with a median follow-up of 10 years, and achieved full donor myeloid and lymphoid engraftment with robust immune reconstitution.<h4>Discussion</h4>These findings demonstrate that <i>AK2</i>-related RD presents with a distinctive neonatal phenotype and carries high pre-transplant mortality, while early HSCT enables durable engraftment and favorable long-term outcomes, supporting the importance of early diagnosis and newborn screening in high-consanguinity populations.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1829403 · PubMed 42112325.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Seven patients underwent HSCT at a median age of 4 months using matched sibling, haploidentical, or cord blood donors; six survived, yielding a post-transplant survival of 85.7% with a median follow-up of 10 years, and achieved full donor myeloid and lymphoid engraftment with robust immune reconstitution.<h4>Discussion</h4>These findings demonstrate that <i>AK2</i>-related RD presents with a distinctive neonatal phenotype and carries high pre-transplant mortality, while early HSCT enables durable engraftment and favorable long-term outcomes, supporting the importance of early diagnosis and newborn screening in high-consanguinity populations.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. A recurrent homozygous missense variant (<i>AK2</i>: NM_001625.4: c.524G>C; p.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1829403. PubMed ID: 42112325. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Alaqeel B, Aljohani F, Alrumayan N et al.. Reticular dysgenesis caused by AK2 deficiency: clinical spectrum and hematopoietic stem cell transplantation outcomes in 10 patients from a single-center.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1829403.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/reticular-dysgenesis-caused-by-ak2-deficiency-clinical-spectrum-and-hema-829403/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides